Welcome to the
NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Sarah Boyce, president and CEO of Avidity Biosciences, who shared insight into the company's ongoing work with its antibody oligonucleotide conjugates (AOC) platform and the focus on myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD) treatments, as well as the challenges with developing successful RNA therapies, and more.
Looking for more neuromuscular disorder discussion? Check out the NeurologyLive® neuromuscular clinical focus page: neurologylive.com/clinical/neuromuscular
Episode Breakdown:
- 1:20 – Current limitations with RNA therapies
- 4:50 – The decision to focus on rare genetic muscle diseases
- 7:45 – The patient needs in DM1, FSHD, and DMD
- 9:05 – Neurology News Minute
- 12:25 – Other clinical areas of focus and collaboration for Avidity
- 14:10 – Upcoming data presentations planned for 2023 in DMD and myotonic dystrophy
- 16:15 – The benefits of collaboration in the rare disease community
- 18:15 – Looking ahead to the future of therapies in rare muscular disease
This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023!
Nominate: neurologylive.com/Giants-of-MS
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Thanks for listening to the
NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit
neurologylive.com.
